Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

Abstract: Novel compounds, compositions, and methods of using and preparing the same, which maybe useful for treating alpha-1 antitrypsin deficiency (AATD).

Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).

Abstract: Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)

Abstract: Indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).

Abstract: 1H-pyrazolo[4,3-g]isoquinoline and 1H-pyrazolo[4,3-g]quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).

Abstract: 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD).

Abstract: Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.

Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).

Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).

Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.

Abstract: A fluid conditioning control system for driving one or more coils in a fluid conditioning system with a target load current to generate an alternating magnetic field directed at a fluid, the control system comprising a controller, a switch mode power supply circuit and a push pull AC drive circuit, wherein the controller is arranged to develop a first variable output having a frequency range that sweeps between a minimum frequency and a maximum frequency, and further arranged to develop a second variable output in the form of a duty cycle controlled signal, wherein the switch mode power supply circuit is arranged to develop a variable supply voltage to the AC drive circuit in response to the second variable output and a current sense circuit, and the AC drive circuit is arranged to develop a drive signal for developing a target load current in response to the first variable output and the variable supply voltage, thereby forming a current feedback loop.

Abstract: A fluid conditioning control system for driving one or more coils in a fluid conditioning system with a target load current to generate an alternating magnetic field directed at a fluid, the control system comprising a controller, a switch mode power supply circuit and a push pull AC drive circuit, wherein the controller is arranged to develop a first variable output having a frequency range that sweeps between a minimum frequency and a maximum frequency, and further arranged to develop a second variable output in the form of a duty cycle controlled signal, wherein the switch mode power supply circuit is arranged to develop a variable supply voltage to the AC drive circuit in response to the second variable output and a current sense circuit, and the AC drive circuit is arranged to develop a drive signal for developing a target load current in response to the first variable output and the variable supply voltage, thereby forming a current feedback loop.

Abstract: A method of transporting a liquid product down a vertical conduit having an inlet provided at the top of the conduit and an outlet provided at the bottom of the conduit, which method comprises feeding the liquid product into the inlet of the conduit and contacting the liquid product with means for dissipating potential energy released by the liquid product as it is transported down the conduit so that turbulence in the liquid product at the outlet of the conduit is reduced.

Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structures VA, VB, VIIA and VIIB where the values of the variables are defined herein.

Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.

Abstract: The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/or tissue ischemia, including myocardial ischemia, and processes for making the compounds.

Abstract: A method of transporting a liquid product down a vertical conduit having an inlet provided at the top of the conduit and an outlet provided at the bottom of the conduit, which method comprises feeding the liquid product into the inlet of the conduit and contacting the liquid product with means for dissipating potential energy released by the liquid product as it is transported down the conduit so that turbulence in the liquid product at the outlet of the conduit is reduced.

Abstract: The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.

Abstract: The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds